Rx Cost Containment At CareFirst Driven By Physician Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
Legal changes that allow more data sharing can encourage value-based contracting, Executive VP-Medical Affairs Blum says
You may also be interested in...
US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight
Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.